The wide acute-toxicity margins for classic psychedelics are real and worth knowing. Rouaud and colleagues in 2024 published a pharmacological safety review reporting therapeutic index estimates of roughly 310 for mescaline, 600 for psilocybin, and over 1000 for LSD, compared with 35 to 50 for caffeine and around 10 for ethanol (Rouaud et al., 2024). That headline number, however, does not describe cardiovascular interaction risk. It describes acute lethality in isolation. The two questions are different, and conflating them is the most common screening error I see in founders preparing for retreats.
The cardiovascular question is narrower and more important for most people in this demographic. Classic psychedelics produce transient blood pressure and heart rate elevation through 5-HT2A and adrenergic mechanisms. The Tabaac and colleagues 2025 cardiovascular safety review in Mass General Advances frames this load as well-tolerated in healthy substrates, but specifically flags hypertension, ischemic heart disease, ventricular arrhythmia, and structural heart disease as contraindication categories (Tabaac et al., 2025). The screening exists to confirm the substrate is healthy before the load is applied.
This guide is structured for founders specifically. The demographic skews toward chronic sleep debt, sympathetic dominance, undiagnosed hypertension, and prescription stimulants. Each of those is a screening flag. For deeper coverage of related topics, see when not to take psychedelics, the afterglow window, glutamate and psychedelics, what happens in an integration session, and psychedelics and high-functioning depression.
- The safety ratio for psilocybin is roughly 600 and for LSD above 1000, versus 35 to 50 for caffeine and 10 for ethanol, per the Rouaud 2024 review in Pharmacological Reports.
- Acute toxicity margin and cardiovascular interaction risk are different questions. Healthy substrates tolerate the transient hemodynamic load well. Compromised substrates often do not.
- The minimum pre-session cardiovascular workup is a multi-visit blood pressure measurement, a resting twelve-lead ECG, a baseline heart rate trend, and a focused medication review.
- Absolute cardiovascular contraindications include uncontrolled hypertension, recent MI or stroke within six months, known ventricular arrhythmia, congestive heart failure, and significant structural heart disease.
- The 5-HT2B valvulopathy concern raised across 2024 reviews applies primarily to extended microdosing protocols, not single-session use. The mechanism is the same one that led to fenfluramine withdrawal.
Why Does Cardiovascular Screening Matter for Founders Specifically?
Founders concentrate cardiovascular risk factors that the general retreat-going population does not. The American Heart Association in 2023 reported that roughly 47 percent of US adults have hypertension under the current threshold of 130 over 80, and the rate climbs in high-stress, sleep-deprived populations. The founder demographic stacks chronic sympathetic activation, prescription stimulants, irregular sleep, and a tendency to underweight body-level signals. Each of those interacts with the acute hemodynamic load of a psychedelic session.
The hemodynamic profile is well-characterized in controlled dose-response work. Hasler and colleagues in 2004, publishing in Psychopharmacology, established psilocybin dose-response curves in healthy human volunteers and documented transient elevations in blood pressure and heart rate that scaled with dose and resolved within hours. The screening conversation rarely happens at the operator level with the depth it should. Retreat operators are not cardiologists. They take a self-reported medical history and rarely require an ECG or a recent blood pressure log. The participant fills out a form, ticks "no known cardiac issues," and the substrate question never gets meaningfully tested. In my work across 900-plus integration sessions, the participants who ran into hemodynamic difficulty during sessions were almost always people whose blood pressure had never been carefully tracked in the months leading up.
The reframe that matters: the screening is not for the retreat operator. It is for you. The retreat will run regardless of how well your cardiovascular system tolerates the load. The question is whether the load is appropriate for your specific substrate, and that question requires evidence beyond a self-report form.
Tabaac and colleagues in 2025 reviewed cardiovascular safety data across psilocybin and LSD clinical trials in Mass General Advances. The transient hemodynamic effects of classic psychedelics include systolic blood pressure increases of approximately 20 to 30 mmHg and heart rate increases of 10 to 20 beats per minute, peaking around 60 to 90 minutes post-dose and resolving over four to six hours. The review frames these effects as well-tolerated by healthy cardiovascular substrates but explicitly flags uncontrolled hypertension, ischemic heart disease, ventricular arrhythmia, and significant structural heart disease as exclusion categories across the major trial protocols. The clinical implication for retreat contexts is that the same screening filter should apply, since the hemodynamic load is identical regardless of whether the session is clinical or underground.
How Wide Are the Safety Margins Really?
The therapeutic index for classic psychedelics is genuinely wide compared with common substances. Rouaud and colleagues in 2024 reported safety ratios of approximately 310 for mescaline, 600 for psilocybin, and over 1000 for LSD, against 35 to 50 for caffeine and roughly 10 for ethanol (Rouaud et al., 2024). These numbers compare lethal dose to effective dose in pharmacological terms. They are not a green light. They are a context number.
What the Safety Ratio Actually Means
A safety ratio of 600 for psilocybin means the lethal dose is roughly 600 times the psychoactive dose. Caffeine at 35 to 50 is far narrower, which is why caffeine overdose is a real if uncommon emergency. Ethanol at 10 is the reason alcohol kills people regularly through acute toxicity alone. The classic psychedelic numbers describe acute single-dose lethality and nothing else.
What the Number Does Not Tell You
The therapeutic index does not describe interaction risk with lithium, MAOIs, or SSRIs. It does not describe cardiovascular interaction with pre-existing hypertension or arrhythmia. It does not describe behavioral risk during an altered state. It does not describe the 5-HT2B valvulopathy concern raised for microdosing. Johnson, Richards, and Griffiths in 2008, publishing in the Journal of Psychopharmacology, framed the safety guidelines for hallucinogen research around exactly these distinctions, emphasizing that screening criteria and setting controls do most of the risk reduction work, not the pharmacological margin itself. Founders who read the safety ratio and conclude the substance is broadly safe are conflating one specific number with overall risk, which is the conflation the cardiovascular screening exists to correct.
What Cardiovascular Tests Should You Complete Before a Retreat?
The minimum pre-session cardiovascular workup is a multi-visit blood pressure measurement, a resting twelve-lead ECG, a baseline heart rate trend across two to four weeks, and a focused medication review. The UCSF Psychedelic Program guidance and the Tabaac 2025 review converge on this base layer. For participants over 40, with hypertension, or with a relevant family history, an echocardiogram and a stress test should be added on top.
Blood Pressure: Multiple Readings, Not One
A single in-office blood pressure reading is not screening. White-coat hypertension is real, and so is masked hypertension, where in-office readings look normal but home readings are elevated. The American Heart Association recommends home blood pressure monitoring across two weeks with morning and evening readings for accurate baseline characterization. The threshold for concern is sustained readings above 130 over 80, and the threshold for absolute contraindication is sustained readings above 140 over 90 or any reading above 160 over 100.
Resting Twelve-Lead ECG
A resting twelve-lead ECG screens for arrhythmia, prolonged QT interval, evidence of prior ischemia, left ventricular hypertrophy, and structural conduction abnormalities. None of these are reliably detectable on physical exam alone. The ECG should be interpreted by a cardiologist, not a primary care physician relying on the automated read. Founders on stimulant medications, with prior caffeine-related arrhythmia symptoms, or with palpitations of any kind should consider extended Holter monitoring across 24 to 48 hours.
Baseline Heart Rate Trend
A two to four week wearable trend of resting heart rate, heart rate variability, and sleep-stage data is one of the most underused pre-session inputs. The reason is that founders frequently have resting heart rates 10 to 20 beats per minute above their healthy baseline because of chronic sympathetic load, and this elevation is invisible to a single-visit measurement. A psychedelic session layered on top of an already-activated sympathetic state produces a different acute experience than the same session on a regulated baseline.
Medication and Supplement Review
The medication review covers prescription stimulants, lithium, MAOIs, SSRIs, SNRIs, blood pressure medications, anticoagulants, and any supplements with cardiovascular activity including high-dose caffeine, yohimbine, pseudoephedrine, and pre-workout formulations. The screening also covers recreational substance use across the prior 30 days, since cocaine and stimulant use produce both immediate and lingering cardiovascular effects that compound psychedelic load.
Which Cardiovascular Conditions Are Absolute Contraindications?
Across MAPS, COMPASS Pathways, and Usona psychedelic trial protocols, the absolute cardiovascular contraindications converge on roughly six categories. The Tabaac 2025 review summarizes these consistently with the UCSF Psychedelic Program medical guidance. The shared logic is that classic psychedelics produce transient hemodynamic load that healthy substrates tolerate well, but compromised substrates may not, and the retreat context cannot provide the monitoring infrastructure that compromised substrates require.
Uncontrolled Hypertension
Sustained blood pressure above 140 over 90, or any reading above 160 over 100, is an absolute contraindication outside of a closely monitored clinical trial. The acute hemodynamic load of psilocybin or LSD can push such readings into hypertensive urgency or emergency territory, with associated risk of stroke, cardiac event, or end-organ damage. Pre-session stabilization through medication adjustment and lifestyle change is a precondition, not a workaround.
Recent Myocardial Infarction or Stroke
Any cardiac event or stroke within six months is an absolute exclusion across all major trial protocols. The recovering cardiovascular system does not have the reserve to absorb the acute psychedelic load. The six-month window is a floor, not a ceiling. Many cardiologists consulted on psychedelic clinical trial eligibility recommend 12-month windows when the event involved significant myocardial damage.
Known Ventricular Arrhythmia
Documented ventricular arrhythmia, including ventricular tachycardia, frequent premature ventricular contractions, and long QT syndrome, is an absolute contraindication. The serotonergic and adrenergic effects of classic psychedelics can lower the arrhythmia threshold in vulnerable individuals. The risk is not theoretical. It is the reason ECG screening is in the base layer of every clinical trial.
Congestive Heart Failure and Structural Heart Disease
Congestive heart failure, significant valvular disease, hypertrophic cardiomyopathy, and active coronary artery disease with ischemic symptoms are absolute exclusions. The acute hemodynamic load of a psychedelic session can precipitate decompensation in these conditions. Pre-session echocardiogram is appropriate for any participant with relevant family history, prior murmur, or symptoms suggestive of structural disease.
The UCSF Psychedelic Program medical contraindications guidance, used to screen participants for clinical research and informed-consent contexts, lists uncontrolled hypertension above 140 over 90, recent myocardial infarction or stroke within six months, congestive heart failure, significant valvular or structural heart disease, known ventricular arrhythmia, and active ischemic coronary artery disease as cardiovascular exclusion criteria. The guidance frames psilocybin and LSD as carrying transient hemodynamic load that healthy substrates tolerate well, with peak blood pressure increases in the range of 20 to 30 mmHg systolic, but explicitly notes that the load is unsafe in compromised cardiovascular systems and that retreat contexts cannot reproduce the monitoring infrastructure that compromised substrates require. The clinical implication is that cardiovascular screening should occur before retreat booking, not after.
Should Microdosers Worry About 5-HT2B Valvulopathy?
The 5-HT2B receptor lives on heart valve fibroblasts, and sustained activation can drive fibroblast proliferation that manifests as valvular fibrosis and regurgitation. This is the same mechanism that led to the withdrawal of fenfluramine (Fen-Phen) in 1997 and pergolide in 2007. Nichols in 2016, publishing in Pharmacological Reviews, mapped the receptor pharmacology of classic psychedelics and documented measurable 5-HT2B affinity for psilocin, LSD, and DMT, providing the receptor-binding context against which the valvulopathy concern is now framed. The question raised across 2024 reviews including Tabaac and colleagues is whether extended microdosing protocols replicate the chronic-exposure profile of those withdrawn medications.
Why Acute Use Is Not the Concern
Single-session high-dose use does not produce the sustained 5-HT2B stimulation that valvulopathy requires. The withdrawn medications were taken daily for months to years. A psychedelic session is one to four doses across a year for most participants in clinical or retreat contexts, and the receptor occupancy resolves within hours of the session. The valvulopathy mechanism does not engage under this exposure profile.
Why Microdosing Is the Open Question
Microdosing protocols typically involve doses every two to four days for weeks or months. The total exposure across a six-month microdosing arc can approach the chronic-exposure profile that drove valvulopathy in fenfluramine populations. The Tabaac 2025 review flags this as an unresolved concern requiring monitoring. The conservative position for founders considering extended microdosing is to obtain a baseline echocardiogram, repeat at six months, and stop the protocol if any valvular abnormality emerges.
What the Honest Framing Looks Like
The valvulopathy concern for microdosing is not proven harm. It is mechanistic plausibility from a well-characterized receptor pathway with a clear historical precedent in two withdrawn medications. The data needed to confirm or rule out the concern in human microdosers does not yet exist. The clinical implication is not "do not microdose." It is "if you microdose for extended periods, monitor for the concern in case the data ends up confirming it."
"The hardest pre-session conversation I have with founders is not about the experience. It is about getting a recent ECG and a two-week home blood pressure log before the retreat. Most resist because it feels bureaucratic. Then I tell them about the participants whose pre-session blood pressure log would have prevented a difficult experience, and the resistance softens."
Rothman and colleagues in 2000, publishing in Circulation, established the mechanistic link between 5-HT2B receptor agonism and valvular heart disease by characterizing the receptor pharmacology of fenfluramine and its active metabolite norfenfluramine. The finding underpinned the 1997 withdrawal of Fen-Phen and the later 2007 withdrawal of pergolide, and it is the same pharmacological framework the European Medicines Agency now applies when evaluating any compound with sustained 5-HT2B affinity. For classic psychedelics, the relevant question is not whether 5-HT2B affinity exists, since it does, but whether the exposure duration in real-world use approaches the chronic-dosing profile that drove the historical valvulopathy cases. Single-session use does not. Extended microdosing protocols may, and the data to settle the question does not yet exist.
The Full Cardiovascular Screening Checklist
The checklist below consolidates the cardiovascular screening considerations covered across this article into a single pre-retreat filter. It is not a substitute for cardiologist evaluation. It is a self-screening tool to surface the specific questions worth bringing to a clinician before any commitment is made. If any absolute item applies, the conservative recommendation is to not pursue a session outside of a monitored research protocol.
Do any of the following apply to you?
- Sustained blood pressure above 140 over 90, or any reading above 160 over 100
- Myocardial infarction, stroke, or transient ischemic attack within the last six months
- Known ventricular arrhythmia, long QT syndrome, or frequent premature ventricular contractions
- Congestive heart failure of any severity
- Significant valvular disease or hypertrophic cardiomyopathy
- Active coronary artery disease with ischemic symptoms
- Currently pregnant, given combined cardiovascular and developmental risk
- Recent seizure history, which overlaps with cardiovascular risk in screening
Have you completed each of the following?
- Home blood pressure log across two weeks, morning and evening readings
- Resting twelve-lead ECG within the last 12 months, interpreted by a cardiologist
- Wearable resting heart rate and HRV trend across two to four weeks
- Medication review covering stimulants, SSRIs, MAOIs, lithium, blood pressure meds, and anticoagulants
- Supplement and recreational substance review across the prior 30 days
- For participants over 40 or with relevant family history: echocardiogram and exercise stress test
- For participants with palpitations, prior stimulant arrhythmia symptoms, or any irregular ECG: 24 to 48 hour Holter monitor
- If considering extended microdosing: baseline echocardiogram with planned six-month repeat